— Financial reporting — Consolidated statement of cash flows
Consolidated statement of cash flows
January 1 – June 30
millions of CHF |
|
Notes |
|
2023 |
|
2022 1) |
|
Cash and cash equivalents as of January 1 |
|
|
|
313.5 |
|
209.8 |
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
7.3 |
|
9.2 |
|
Loss on net assets derecognized and retained investment |
|
14 |
|
– |
|
15.4 |
|
Interest income |
|
6 |
|
–0.3 |
|
–0.0 |
|
Interest expenses |
|
6 |
|
4.2 |
|
3.0 |
|
Income tax expenses |
|
7 |
|
1.7 |
|
4.5 |
|
Depreciation, amortization and impairments |
|
|
|
25.6 |
|
24.7 |
|
(Gains) / losses from disposals of tangible and intangible assets |
|
|
|
0.0 |
|
0.0 |
|
Changes in inventory |
|
|
|
–6.4 |
|
–12.1 |
|
Changes in advance payments to suppliers |
|
|
|
–0.5 |
|
–3.2 |
|
Changes in contract assets |
|
|
|
–1.2 |
|
–0.4 |
|
Changes in trade accounts receivable |
|
|
|
–7.3 |
|
–24.3 |
|
Changes in contract liabilities |
|
|
|
–0.2 |
|
–1.1 |
|
Changes in trade accounts payable |
|
|
|
3.8 |
|
3.1 |
|
Changes in employee benefit plans |
|
|
|
–0.3 |
|
–6.3 |
|
Changes in provisions |
|
|
|
–0.9 |
|
–1.2 |
|
Changes in other net current assets |
|
|
|
–1.1 |
|
18.7 |
|
Other non-cash items |
|
|
|
–1.9 |
|
4.2 |
|
Interest received |
|
|
|
0.3 |
|
0.0 |
|
Interest paid |
|
|
|
–3.1 |
|
–2.6 |
|
Income tax paid |
|
|
|
–4.5 |
|
–5.6 |
|
Total cash flow from operating activities |
|
|
|
15.4 |
|
26.1 |
|
|
|
|
|
|
|
|
|
Purchase of intangible assets |
|
|
|
–1.4 |
|
–0.7 |
|
Purchase of property, plant and equipment |
|
|
|
–18.9 |
|
–12.0 |
|
Sale of property, plant and equipment |
|
|
|
0.0 |
|
0.8 |
|
Cash consideration for acquisitions, net of cash acquired |
|
|
|
–0.0 |
|
–0.0 |
|
Deconsolidation of medmix Poland, cash derecognized |
|
|
|
– |
|
–2.0 |
|
Divestitures of investments in subsidiaries |
|
|
|
4.0 |
|
– |
|
Sale of other non-current financial assets |
|
|
|
– |
|
0.1 |
|
Purchase of current financial assets |
|
|
|
–0.0 |
|
0.0 |
|
Sale of current financial assets |
|
|
|
3.3 |
|
0.2 |
|
Total cash flow from investing activities |
|
|
|
–13.0 |
|
–13.6 |
|
|
|
|
|
|
|
|
|
Dividends paid to shareholders |
|
8 |
|
–7.9 |
|
–15.0 |
|
Purchase of treasury shares |
|
8 |
|
–1.0 |
|
–6.1 |
|
Payments of lease liabilities |
|
|
|
–4.9 |
|
–4.5 |
|
Repayments of non-current borrowings |
|
9 |
|
– |
|
–2.6 |
|
Proceeds from current borrowings |
|
9 |
|
2.0 |
|
153.8 |
|
Repayments of current borrowings |
|
9 |
|
–156.8 |
|
–158.5 |
|
Total cash flow from financing activities |
|
|
|
–168.6 |
|
–32.8 |
|
|
|
|
|
|
|
|
|
Exchange gains / (losses) on cash and cash equivalents |
|
|
|
–1.8 |
|
–0.7 |
|
|
|
|
|
|
|
|
|
Net change in cash and cash equivalents |
|
|
|
–167.9 |
|
–21.0 |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents as of December 31 |
|
|
|
145.6 |
|
188.9 |
|
1) The numbers as of June 30, 2022, have been adjusted following the deconsolidation of medmix Poland. A reconciliation to the previously published numbers is provided in note 14.